Aug. 29 at 6:10 PM
$XBI 3 Cancer Fighting 10 x Gainer Gems:
$SLS $DRTS $PSTV - PSTV has been selling it's CNSide Assay to major cancer treatment centers in Texas for 30 days now. If it's selling to hospitals for at least
$2,800 now (PTSV paid Biocept
$2800/per CNSide test post acquisition per contract, CNSide now has 2 certifications vs. none then, targets three types of patients vs. one, and the tests have been substantially improved) it only takes 500 sales per month to generate
$1.4MM in sales. That's doable once we are licensed to sell in at least 25 states because one cancer patient could benefit from 2-3 tests per year and other patients could benefit from using it proactively for early detection. If we are conservative and say we do not reach 500 B2B sales per month until Q1 2026, that's still
$1.4MM/month in sales x 12 months =
$16.8M in CNSide sales in 2026. PSTV's first FDA approval will be sooner vs. later because there's no FDA approved therapy that's effective for glioblastoma! 1 YR PT
$10
